The role of GPER becomes essential under such circumstances, and it has been reported that a selective agonism of GPER by the agonist G-1 can mitigate obesity and metabolic dysfunction symptoms in many murine models, thereby curtailing weight gain, diminishing insulin resistance and inflammation, and enhancing glucose and lipid homeostasis in vivo [294]. The gene discussed is INS; the disease is Obesity.